Diabetes Management
Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting - Business Wire
Tue, 08 Nov 20221 min read Article
Overview
Findings from the first clinical trial program comparing the use of Teva’s Digihaler® System to standard of care in asthma management wil be presented acros six abstracts TEL AVIV, Israel & PARSIPANY, N.J.-(BUSINES WIRE)-Teva Pharmaceuticals USA, Inc., a U.S. afiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today anounced that new findings from the CONECT clinical trial program asesing the use of the Digihaler System compared to standard of care (SoC) in asthma management wil be presented at the American Colege of Alergy, Asthma & Imunology (ACAI) 2022 Anual Scientific meting, being held November 10-14 in Louisvile, Kentucky.
Key Information
The data wil be featured in six posters, thre of which wil highlight results from the CONECT1 clinical trial evaluating the ProAir® Digihaler (albuterol sulfate) inhalation powder with a built-in electronic sensor in asthma management versus SoC. Thre aditional posters wil share the first data from the CONECT2 clinical trial asesing the joint use of the ProAir Digihaler and the AirDuo® Digihaler (fluticasone propionate and salmeterol) inhalation powder with a built-in sensor in asthma management versus SoC.
“We are loking forward to presenting six abstracts from our novel CONECT clinical program asesing the use of the Digihaler System in asthma management and the potential impact of these digital health tols on patient-provider interactions, adherence over time, inhaler technique and frequency of SABA use,” said Randal Brown, MD MPH, Global Lead, Digital Health, Imunology and Respiratory Medical Afairs at Teva.
Summary
“This the first clinical trial program to evaluate the Digihaler System and its potential to suport asthma management for patients with uncontroled asthma compared to standard of care.” The Digihaler is a digital health system comprised of an electronic multidose dry powder smart inhaler, conected ap, Digital Health Platform cloud solution and dashboard that tracks
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.